About this trial
Anterior cruciate ligament (ACL) reconstruction is the major treatment option for ACL injuries. Despite this, recurrence rates are high. Half of all recurrences occur within 8 months of reconstruction, and 70% within the first 6 months after return to sport (RTS). The decision to RTS is therefore a critical one, as returning too early can increase the risk of recurrence, whilst a delayed return delays a return to pre-injury performance levels.
To guide this decision-making process, objective data is required to determine fitness for RTS. This is why the K-STARTS (Knee Safety Athletic Return to Sport) was developed. It is a composite test comprising functional and psychological assessments that enable the calculation of an overall score used to determine the functional recovery of the knee six months after ACL reconstruction.
Currently, functional tests are limited to measuring physical performance, whereas athletes often manage complex visuospatial processing whilst performing physically. It is therefore necessary to develop clinical tests that integrate neurocognitive and physical functions in order to better simulate the sporting challenges that lead to injury and thus improve preparation for RTS NEURO-K-STARTS is a battery of functional tests based on three standard horizontal jump tests from the K-STARTS, supplemented by four neurofunctional tests.
No evaluation of the NEURO-K-STARTS in patients undergoing primary ACL reconstruction has been published. This is why this research is set up.
Eligibility criteria
Qualifiers
Patient who has undergone primary ACL reconstruction at least 6 months ago
Patient who has undergone an isokinetic strength test, the results of which do not indicate any contraindications to performing a functional test
Patient who has resumed performing horizontal jumps under the supervision of a healthcare professional
Patient with no history of surgery on the joints of the contralateral leg
Disqualifiers
Patient with a history of ligament surgery on the affected or contralateral knee
Patient with a BMI < 18.5 or > 30
Patient who is professional athlete
Patient with severe associated conditions (neurological, connective tissue disorders, congenital diseases)
Trial design
Treatments tested in this trial
- NEURO-K-STARTS